https://doi.org/10.31288/oftalmolzh201342429

Expression P53, BCL-2, CD95 and IPO-38 SN malsgnant epstelsal tumors of the eyelid skin with an aggressive course

V. V. Vit, I. A. Safronenkova

SI «The Filatov Institute of Eye Diseases and Tissue Therapy NAMS of Ukraine»

e-mail: safronenkova@ukr.net

Introduction. Malignant epithelial tumors (Theo) of the eyelid skin have a broad spectrum of biological behavior — from existing for years and decades of stationary non-invasive forms of progressing to aggressive options with deep local destru-irujushchego growth. It is known that a significant role in neoplastic cell transformation and progression of malignant neoplasms belongs inactivation of regulatory proteins controlling cell proliferation and apoptosis. Therefore, it is important to study the proliferative and pro-and anti-apoptotic activity in aggressive forms Theo eyelid skin.

Purpose — the study of immunohistochemicalproliferative indices (IPO38), pro-and anti-apoptotic activity (CD95, Bcl-2 andp53) Theo eyelid skin with an ag-gressive course.

Material and methods. Immunohistochemical studies were carried out using monoclonal antibody Bcl-2, p53 and CD95 IPO38 biopsies and tumor tissue after orbital exenteration 9patients with Theo eyelid skin (4 males and 5 females) aged34 to 75 years (median 60.6) treated with combination therapy (radiotherapy + cryoablation) in SI «Institute of Eye Diseases and Tissue Therapy. Filatov NAMS of Ukraine «in 2000—2008years.

Results. Found that for Theo eyelid skin with an aggressive course characterized by hyperoverexpression ofp53 (85,6±7,3) % and IPO38 (95,0±13,2) %, hypoek-spression Bcl-2 (10,0±3,6) % and the lack of expression of CD95. This indicates a high proliferative potential and reduced apoptotic activity of the tumor. Conclusion. Determine the value of molecular markers associated with proliferative and apoptotic activity Theo eyelid skin. Increased expression of proliferative markers p53 and IPO38, reducing the antiapoptotic marker Bcl-2 and the lack of expression of the marker CD95 inducer of apoptosis characterize the biological aggressiveness of tumors

Key words: malignant epithelial tu¬mors of the eyelid skin, markers p53, Bcl-2, CD95, IPO38

References

1.Gluzman DF, Sklyarenko LM, Nadgornaya VA. Diagnostic immunocytochemistry of tumors. Kiev: Morion; 2003: 6-15.

2.Zaridze DG, Alev GI, Altshtein AD, Belitskii GA. Carcino-genesis: (Manual). M.: Meditsina; 2004. 576 p.

3.Kopnin BP. The target of the oncogenes and tumor sup-pressor: the key to understanding the basic mechanisms of carcinogenesis. Biokhimiia. 2000; 65(1): 5—33. Russian.

4.Kolesnik AP, Palamarchuk ID, Sidorenko AM. Molecular markers of progression of colorectal cancer. Onkologiia. 2006; 1: 13—7. Russian.

5.Maslyakov GN, Ponukalin AN, Tsmokalyuk EN et al. The role of immunohistochemical markers in the diagnosis of bladder cancer. Saratovskii nauchno-meditsinskii zhurnal. 2009; 4(5): 608—11. Russian.

6.Safronenkova IA. Expression of oncoproteins p53, Bcl-2 and antigen CD95, IPO38 in patients with malignant epithelial tumors of the eyelids. Oftalmol Zh. 2012; 3: 53—7. Russian.
Crossref

7.Chuprov IN. Clinical — morphological characteristics of different types of basal cell skin cancer growth. Vestnik Sankt-Peterburgskogo Universiteta. Seriia 11. Meditsina. 2009; 1: 145—51. Russian.

8.Grishchenko PO, Kovtunenko OV, Shponka IS et al. Pre-diction of clinical current of cancer of the larynx in an in-tegrated immunohistochemical study. Zhurnal vushnykh, nosovykh i gorlovykh khvorob. 2006; 5: 35—6. Ukrainian.

9.Ansarin H, Daliri M, Soltani-Arabshahi R. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma. Eur. J. Dermatol. 2006;16(5): 543- 7.

10.Auepemkiate S, Boonyaphiphat P, Thongsuksai P. P53 ex-pression related to the aggressive infiltrative histopatholog-ical feature of basal cell carcinoma. Histopathology. 2002; 40(6): 568- 73.
Crossref

11.Hobart W. Walling, Scott Fosco W, Pedram Geraminejad A et al. Aggressive basal cell carcinoma: Presentation, patho-genesis and management. Cancer and Metastasis Reviews. 2004; 23: 389-402.
Crossref

12.Lukyanova NYu, Kulik GI, Yurchenko OV et al. Expression of p53 and Bcl-2 proteins in epithelial ovarian carcinoma with different grade of differentiation. Experimental Oncology. 2000; 22(1): 91-3.

13.Mikhalap S, Shlapatska L, Berdova A et al. Monoclonal antibody IPO-38 in evaluation of proliferative activity of tumor cells. Experimental Oncology. 2000; 22(2): 36- 8.

14.Nakopoulou L, Mylona E, Papadaki I et al. Study of phos-phor-p-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Modern Pathologi. 2006: 19: 556- 3.
Crossref

15.Rohbach JM, Stiemer R, Mayer A et al. Immunology and growth characteristics of ocular basal cell carcinoma. Graefe's Arch. Clin. Exp. Ophthalmol. 2001; 239: 35- 40.
Crossref

16.Stoenescu TM, Ivan LD, Stoenescu N et al. Assessment tumor markers by immunohistochemistry (Ki67, p53 and Bcl-2) on a cohort of patients with cervical cancer in various stages of evolution. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2011; 115(2): 485-92.